Core Viewpoint - Cuprina Holdings reaffirms its operational stability and commitment to advancing its biotechnology pipeline amidst recent stock volatility, emphasizing transparency and long-term value for stakeholders [2][3][4]. Company Operations - Cuprina is a fully operational and legally compliant biotechnology company focused on biotherapeutic solutions [2]. - The company is executing its business plan effectively since its Initial Public Offering earlier this year [3]. - Cuprina is exploring potential joint ventures and mergers & acquisitions to enhance chronic wound management products [4]. Financial and Market Position - The company has not observed any operational reasons for the recent stock price volatility and reports no material adverse events [3]. - None of the initial shareholders or founding team members have sold their stock recently, indicating confidence in the company's mission and growth potential [4]. Future Developments - Cuprina is on track with its operational and regulatory milestones, including the submission of FDA clearance for its medical maggot therapy and expansion of maggot distribution to the Gulf Cooperation Council (GCC) region [7]. - The company is committed to keeping shareholders updated on key developments through timely disclosures and filings [5]. Company Background - Cuprina Holdings is based in Singapore and specializes in the development and commercialization of innovative products for chronic wound management, utilizing materials derived from natural sources [6].

Medicinal leeches are increasingly used in the GCC to treat diverse medical conditions including venous congestion, which is a buildup of blood in the veins, and to aid in tissue healing and circulation following reconstructive and microsurgery procedures. The leeches are also used to relieve symptoms of osteoarthritis as well as in veterinary surgery, especially to help treat polycythaemia vera, a chronic blood cancer. "We are excited to complete both of these milestones," said Cuprina chief executive Davi ...